07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase I/II data

Data from 14 evaluable pediatric patients in an open-label, U.S. Phase I/II trial showed that twice-daily subcutaneous Xerecept reduced daily dexamethasone dosing requirements by >50% in 10 patients, 5 of which were able to completely...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Urocortin 2: Phase II data

The double-blind, New Zealand Phase II UNICORN trial in 53 patients with ADHF showed that IV urocortin 2 was generally well tolerated with no treatment-related serious adverse events reported. Urocortin 2 significantly reduced mean arterial...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase I/II data

Data from 15 pediatric patients in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that Xerecept led to "substantial" reductions in daily dexamethasone dosing requirements in all patients, with about...
07:00 , Jun 28, 2010 |  BioCentury  |  Strategy

Indi-Plan B Takes Shape

Neurocrine Biosciences Inc. hopes a pair of recent deals will be transformational for the company in much the same way its 2002 indiplon partnership with Pfizer Inc. was for the biotech's last incarnation - but...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase I/II started

Celtic began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate 10, 20, 30 and 40 µg/kg subcutaneous Xerecept given twice daily in up to 60 pediatric patients. Celtic acquired exclusive, worldwide rights to Xerecept...
07:00 , Aug 20, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Anxiety Corticotropin-releasing factor (CRF);...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase II data

Celtic Pharmaceutical Holdings L.P., Hamilton, Bermuda   Neurobiological Technologies Inc. (NASDAQ:NTII), Emeryville, Calif.   Product: Xerecept corticorelin   Business: Cancer   Molecular target: Corticotropin-releasing factor (CRF) receptor 1; Corticotropin-releasing factor (CRF) receptor 2   Description: Synthetic human...
07:00 , Jul 24, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology ...
07:00 , Mar 13, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

Xerecept corticotropin releasing factor: Discontinue Phase III enrollment

Celtic said it will discontinue enrollment in the double-blind, placebo-controlled, international Phase III NTI 0302 trial comparing Xerecept to dexamethasone due to slow enrollment and the expectation that a third planned Phase III trial (CPDS...